Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer

Uzma Asghar, Alexis R. Barr, Ros Cutts, Matthew Beaney, Irina S. Babina, Deepak Sampath, Jennifer M. Giltnane, Jennifer A. Lacap, Lisa Crocker, Amy Young, Alex Pearson, María Teresa Herrera-Abreu, Chris Bakal, Nicholas C. TurnerClinical 2017 · DOI

Abstract

<b>Purpose:</b> Triple-negative breast cancer (TNBC) is a heterogeneous subgroup of breast cancer that is associated with a poor prognosis. We evaluated the activity of CDK4/6 inhibitors across the TNBC subtypes and investigated mechanisms of sensitivity.<b>Experimental Design:</b> A panel of cell lines representative of TNBC was tested for <i>in vitro</i> and <i>in vivo</i> sensitivity to CDK4/6 inhibition. A fluorescent CDK2 activity reporter was used for single-cell analysis in conjunction with time-lapse imaging.<b>Results:</b> The luminal androgen receptor (LAR) subtype of TNBC was highly sensitive to CDK4/6 inhibition both <i>in vitro</i> (<i>P</i> < 0.001 LAR vs. basal-like) and <i>in vivo</i> in MDA-MB-453 LAR cell line xenografts. Single-cell analysis of CDK2 activity demonstrated differences in cell-cycle dynamics between LAR and basal-like cells. Palbociclib-sensitive LAR cells exit mitosis with low levels of CDK2 activity, into a quiescent state that requires CDK4/6 activity for cell-cycle reentry. Palbociclib-resistant basal-like cells exit mitosis directly into a proliferative state, with high levels of CDK2 activity, bypassing the restriction point and the requirement for CDK4/6 activity. High CDK2 activity after mitosis is driven by temporal deregulation of cyclin E1 expression. CDK4/6 inhibitors were synergistic with PI3 kinase inhibitors in <i>PIK3CA</i>-mutant TNBC cell lines, extending CDK4/6 inhibitor sensitivity to additional TNBC subtypes.<b>Conclusions:</b> Cell-cycle dynamics determine the response to CDK4/6 inhibition in TNBC. CDK4/6 inhibitors, alone and in combination, are a novel therapeutic strategy for specific subgroups of TNBC. <i>Clin Cancer Res; 23(18); 5561-72. ©2017 AACR</i>.
BibTeX
@inproceedings{asghar2017single,
  author = {Uzma Asghar and Alexis R. Barr and Ros Cutts and Matthew Beaney and Irina S. Babina and Deepak Sampath and Jennifer M. Giltnane and Jennifer A. Lacap and Lisa Crocker and Amy Young and Alex Pearson and María Teresa Herrera-Abreu and Chris Bakal and Nicholas C. Turner},
  title = {{Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer}},
  booktitle = {Clinical},
  year = {2017},
  doi = {10.1158/1078-0432.ccr-17-0369},
}

Loading related content...

Figure